The agreement is aligned with Osteotec’s mission to improve surgical outcomes in bone repair. Credit: Kenny Eliason on Unsplash.

Osteotec has signed an exclusive agreement for the distribution of Cerapedics’ i-FACTOR bone graft portfolio in Ireland and the UK.

The agreement is aligned with Osteotec’s mission to improve surgical outcomes in bone repair. The distribution deal refers to products such as the i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR, which are used in spine procedures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Cerapedics’ i-FACTOR portfolio is distinguished by its P-15 osteogenic cell-binding peptide, a unique feature that accelerates new bone formation by attaching and activating osteogenic cells.

This mechanism of action is exclusive to Cerapedics’ products and has been clinically validated.

The i-FACTOR Bone Graft, leveraging the P-15 peptide, is the only biologic bone graft composed of a small peptide bound to an anorganic bone mineral. This combination facilitates a surface-bound mechanism that promotes natural bone healing while preventing ectopic bone growth.

Unlike engineered growth factors, i-FACTOR Bone Graft’s P-15 peptide specifically activates cells predestined to become osteoblasts.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Effective as of 1 December, the agreement aims to significantly boost sales and revenue while driving the growth of both companies. It also combines Cerapedics’ product design with Osteotec’s market expertise to foster the adoption of i-FACTOR products in the region.

Cerapedics International general manager Stewart Jefferson said: “This partnership is an important step in our global growth strategy.

“Osteotec’s established market presence and commitment to service excellence make them an ideal partner. Together, we are confident we can deliver effective solutions to surgeons while improving patient outcomes throughout the UK and Ireland.”

Osteotec sales and marketing director Dean Stockwell said: “At Osteotec, we are committed to delivering best-in-class solutions that empower surgeons to achieve optimal patient outcomes.

“Our partnership with Cerapedics enhances our ability to meet the evolving needs of our customers by providing access to advanced biologics.”

In June 2024, Osteotec partnered with TriMed for the distribution of the Osteotec Silicone Finger Implant in the US.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now